Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Experimental Study on Alcohol Use and Behavior in Young Adults

A legfontosabb adatok

Ki végzi
Karolinska Institutet
Hol
Svédország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
206 fő vett részt
Kezdés
2023. okt. 17.
Befejezés
2025. ápr. 23.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • Oxytocin nasal spray
A regiszteradat frissítve
2025. május 7.
Miért állt le
Halted due to recruitment problems.

Ki vehet részt

Életkor
18 év – 24 év
Nem
Csak férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • 18-24 years of age
  • Male
  • Give informed consent and comply with study procedure
  • Understands written Swedish; Alcohol use disorder (AUD) group
  • Fulfils criteria for at least moderate AUD the past 12 months according to MINI Neuropsychiatric Interview
  • Fulfils at least 8 points on the Alcohol Use Disorder Identification Test; Healthy control group
  • No criteria for AUD the past 12 months according to MINI Neuropsychiatric Interview
  • Fulfils less than 8 points on the Alcohol Use Disorder Identification Test

Ki nem vehet részt

  • Cannabis use on day of testing or day before testing
  • Using non-prescription medicine that could not be stopped 48 hours prior to each visit
  • Using intranasal medicine that could not be stopped 48 hours prior to each visit
  • Fulfils criteria for any substance use disorder (except AUD for AUD-group, and mild cannabis- and nicotine use disorder for both groups)
  • History of severe psychiatric disorder (e.g. severe depression, bipolar, antisocial personality disorder) or neuropsychiatric disorder of ADHD, autism or Tourette's
  • Medical conditions of such severity that they require continual clinical attention, such as regular follow-up visits, prescribed medications or other specific treatment
  • Allergy or intolerance to preservatives in nasal spray, e.g. latex allergy
  • Upper-respiratory tract infection (i.e. a 'common cold' resulting in significant nasal congestion) at day of testing (but with the possibility of rescheduling for another time point)
  • History of nasal disease (e.g. atrophic rhinitis, recurrent nose bleeds), nose damage (e.g. broken nose), and nasal surgery
  • History of head trauma (i.e. loss of consciousness longer than 2 minutes)
  • Using cocaine, amphetamines, hallucinogens, benzodiazepines, etc. within 1 month of the start of the study (excluding cannabis)
  • Cannabis use more than 2 days in past month
  • Traces of alcohol as measured by breathalyzer on the day of testing
  • Prescription medicine the past 3 months
  • Prescription medicine the past 3 months
  • Simultaneous participation in another clinical trial

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this double blind randomized placebo-controlled clinical trial is to compare intranasal oxytocin and placebo in young adult individuals with alcohol use disorder as compared to healthy controls. The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

* The effect of oxytocin versus placebo on prosocial behavior in individuals with high- versus low alcohol use * The effect of oxytocin versus placebo on impulsivity, emotion recognition, social learning, and alcohol craving in individuals with high- versus low alcohol use

Participants in both groups will on two separate visits perform the following validated behavioral task measures:

* Dictator game tasks assessing prosocial behavior * Delay discounting task assessing impulsivity * Emotion recognition task assessing emotion recognition * Alcohol cue craving task assessing alcohol craving * Observational fear learning task assessing social learning

Researchers will compare groups of high and low alcohol use to see if there is a difference in effect of oxytocin versus placebo between groups.

A vizsgálat 4 csoportja

  • Oxytocin/Placebo, Alcohol Use DisorderA vizsgált kezelés

    Visit 1: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures Visit 2: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures

    Kezelés: Oxytocin nasal spray

  • Placebo/Oxytocin, Alcohol Use DisorderA vizsgált kezelés

    Visit 1: Alcohol Use Disorder participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures Visit 2: Alcohol Use Disorder participants will receive 24 IU of oxytocin prior to completing behavioral task measures

    Kezelés: Oxytocin nasal spray

  • Oxytocin/Placebo, Healthy ControlA vizsgált kezelés

    Visit 1: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures Visit 2: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures

    Kezelés: Oxytocin nasal spray

  • Placebo/Oxytocin, Healthy ControlA vizsgált kezelés

    Visit 1: Healthy Control participants will receive 24 IU of placebo (saline solution) prior to completing behavioral task measures Visit 2: Healthy Control participants will receive 24 IU of oxytocin prior to completing behavioral task measures

    Kezelés: Oxytocin nasal spray

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2025. május 7.